Full Press Release Details
Can-Fite Applies for Orphan Drug Designation
in Europe for CF102 in the Treatment of Liver Cancer
Designation would provide study
protocol assistance and market exclusivity
PETACH TIKVA, Israel, April 20, 2015
-- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule
drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted
an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment
of hepatocellular carcinoma (HCC), the most common form of liver cancer.
CF102 is currently in a Phase II trial
in the U.S., Israel, and Europe. The study enrolls HCC patients with Child-Pugh Class B cirrhosis who failed the only FDA approved
drug on the market, Nexavar (sorafenib). The patients are treated twice daily with 25 mg of CF102, which has been found to be the
most efficacious dose in our earlier Phase I/II study resulting in the longest overall survival time. CF102 is a stable drug which
is hardly metabolized in the liver and therefore is suitable for treatment of liver diseases. In addition, the 25 mg dose had an
excellent safety profile in the Phase I/II study and showed no hepatotoxicity and even maintained liver function in patients with
advanced liver disease.
Can-Fite has already been granted Orphan
Drug Status for CF102 for the indication of HCC by the U.S. Food and Drug Administration. CF102 is also approved for Compassionate
Use by Israel's Ministry of Health.
If CF102 is granted Orphan Drug Designation
in Europe, Can-Fite would benefit from incentives including protocol assistance, fee reductions, and market exclusivity once the
medicine is on the market for up to 10 years in European Union member nations.
"As we are currently conducting
our Phase II trial for CF102 in the treatment of liver cancer, we believe this is an opportune time for us to apply for Orphan
Drug Designation in Europe. If our Phase II study results are favorable, then this designation would grant us the European Medicines
Agency's valuable assistance in the development of our Phase III study protocol," stated Pnina Fishman, CEO of Can-Fite.
"Upon marketing approval, receiving market exclusivity for CF102 would be significantly beneficial to Can-Fite."
According to Global Industry Analysts,
the global market for liver cancer is projected to exceed $2 billion by 2015.
CF102 is a small orally bioavailable
drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). A3AR is highly expressed in tumor cells
whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.
In Can-Fite's pre-clinical and clinical studies, CF102 has demonstrated a robust anti-tumor effect via deregulation of the Wnt
signaling pathway, resulting in apoptosis of liver cancer cells. CF102 is in Phase II clinical trials for the treatment of liver
cancer in the U.S., Israel, and Europe. The U.S. Food and Drug Administration has agreed with Can-Fite's Phase II study protocol
and had previously granted Can-Fite Orphan Drug Designation for CF102 in the treatment of hepatocellular carcinoma, the most common
form of liver cancer.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE MKT:
CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address
multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's CF101
recently completed Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial
for rheumatoid arthritis. Can-Fite's liver cancer drug CF102 is in Phase II trials and has been granted Orphan Drug Designation
by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon,
prostate, and melanoma. The Company's CF602 has shown efficacy in the treatment of erectile dysfunction. Can-Fite has initiated
a full pre-clinical program for CF602 in preparation for filing an IND with the U.S. FDA in this indication. These drugs have
an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit:
Forward-Looking Statements
This press release may contain forward-looking
statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its
representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified
by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may,"
"should" or "anticipate" or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press
releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and
in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly
volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to
publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.